PurposeTo investigate the effects and mechanisms of fenofibrate, a synthetic ligand of peroxisome proliferator-activated receptor α (PPAR-α), on autoimmune dacryoadenitis in a mouse model of Sjögren syndrome (SS) dry eye.MethodsMale nonobese diabetic (NOD) mice were fed chow with or without 0.03% fenofibrate for 8 weeks, and clinical scores were de...
Published in Archives of biochemistry and biophysics
Benign prostatic hyperplasia (BPH) is one of the most age-related health problems that commonly affect men. Regrettably, many individuals may not respond to current medical therapies or develop resistance to them. Accordingly, this study aimed to uncover how potentially fenofibrate, a lipid lowering agent, can ameliorate the induced BPH in rats. Fo...
Published in Gynecologic and Obstetric Investigation
Objective: In the present study, we attempted to identify the effects of fenofibrate on human cervical cancer cells. Methods: The cytotoxicity of fenofibrate in cervical cancer cells was determined by Cell Counting Kit-8. Immunoblotting assay was used to determine the protein expression of caspase-3, poly ADP-ribose polymerase cleavage, B-cell lymp...
Published in Journal of Applied Oral Science
Inflammation-related immune responses and bone metabolism lead to extensive tooth loss in periodontitis. Objective: This study aims to investigate the effect of peroxisome proliferator-activated receptor (PPAR) alpha agonist anti-inflammatory treatment in vitro and in ligature-induced experimental periodontitis in vivo . Methodology: Splenocytes we...
Published in Biochemistry and Biophysics Reports
• Fenofibrate reduced cisplatin-induced apoptosis in mProx cells. • Fenofibrate reduced caspase-3 activation by inhibiting p53/Puma/caspase-9 pathways. • Fenofibrate reduced caspase-8 activation by inhibiting MAPK/death receptor pathways. • Fenofibrate promoted autophagy in mProx cells under starvation conditions. • Autophagy inhibition, however, d...
Published in Current drug delivery
Fenofibrate (FNB) is a commonly used hypolipidemic agent. However, the oral bioavailability of FNB is limited by slow dissolution due to its low solubility. Thus, investigations on novel FNB formulations are necessary for their use. The objective of this study is to enhance the oral bioavailability of FNB using optimized Nanostructured Lipid Carrie...
Published in Cardiology Research
Background Dyslipidemia is one of the major risk factors for cardiovascular disease (CVD), along with hypertension, diabetes, smoking and obesity. Approximately 70% of CVD risk remains even after treatment of elevated low-density lipoprotein-cholesterol (LDL-C) by statins. High triglyceride (TG) and low high-density lipoprotein-cholesterol (HDL-C) ...
Published in Atherosclerosis
Published in Annals of Medicine and Surgery
In December 2019, a severe pneumonia-like illness emerged in the city of Wuhan, China which inevitably led to the Coronavirus disease-19 (COVID-19) pandemic caused by the SARS-CoV-2 virus. Due to the increase in infectivity and mortality caused by the virus, multiple therapeutic regimens are being suggested in order to help tackle this problem. The...
Published in European Journal of Pharmaceutics and Biopharmaceutics
Drug solubility is a key parameter controlling oral absorption, but intestinal solubility is difficult to assess in vitro. Human intestinal fluid (HIF) aspirates can be applied but they are variable, difficult to obtain and expensive. Simulated intestinal fluids (SIF) are a useful surrogate but multiple recipes are available and the optimum is unkn...
